Specialties

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 4 of this Exclusive Interview, Dr. Taub explains when and how she continues to work with diabetes patients versus referring them to a specialist. Dr. Pam R. Taub, MD, FACC is a …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 5 of this Exclusive Interview, Dr. Taub explains her effective methods of treating the patient that may benefit other medical professionals. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 6 of this Exclusive Interview, Dr. Taub discusses calcium scores and starting patients on PCSK9. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on general and preventive cardiology. …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 7 of this Exclusive Interview, Dr. Taub explains her comfort level with the newest drugs. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on general and preventive cardiology. …

Dr. Pam R. Taub talks with Diabetes in Control Publisher Steve Freed at the 2016 AACE Meeting. In part 8, the conclusion of this Exclusive Interview, Dr. Taub shares her findings after using new medications with her patients. Dr. Pam R. Taub, MD, FACC is a board-certified cardiologist who focuses on …

What do we need to tell our patients about preventing the risk for death?

Study data show fasting glucose concentrations of at least 100 mg/dL (5.6 mmol/L) or an HbA1c of at least 5.7% (39 mmol/mol) were determining factors.

The results from a new study show that risk increased in women with an early HbA1c of at least 5.9% regardless of a gestational diabetes diagnosis later in pregnancy.

Liraglutide, on top of stable renin angiotensin system (RAS)-inhibition, is associated with significant reduction in albuminuria among patients with type 2 diabetes and persistent microalbuminuria.

Study finds treatment on top of stable renin angiotensin system (RAS)-inhibition decreased risk.